Novartis says SMA gene therapy is cost-effective at $4 million to $5 million per patient

Novartis says its new gene therapy for spinal muscular atrophy could be cost-effective for health care systems despite costing up to $5 million per patient, according to Dave Lennon, president of AveXis, a U.S. gene therapy developer acquired by Novartis earlier this year.

Novartis says its new gene therapy for spinal muscular atrophy could be cost-effective for health care systems despite costing up to $5 million per patient, according to Dave Lennon, president of AveXis, a U.S. gene therapy developer acquired by Novartis earlier this year. Speaking on a call with investors, Lennon said: "We've shown through other studies we are cost effective in the range of $4-$5 million. And ultimately, this is important context as we consider how we're going to evaluate value for (the therapy called) AVXS-101." Novartis CEO Vas Narasimhan added that Novartis was not yet ready to comment on commercial pricing for the one-time therapy, which would be determined in talks with insurers and government payers in the United States and elsewhere around the world.